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ABSTRACT
Several histone deacetylase inhibitors including Vorinostat have received 
FDA approval for the treatment of haematological malignancies. However, data 
from these trials indicate that Vorinostat has limited efficacy as a monotherapy, 
prompting the need for rational design of combination therapies. A number of epi-
sensitised pathways, including sonic hedgehog (SHH), were identified in AML cells 
by integration of global patterns of histone H3 lysine 9 (H3K9) acetylation with 
transcriptomic analysis following Vorinostat-treatment. Direct targeting of the SHH 
pathway with SANT-1, following Vorinostat induced epi-sensitisation, resulted in 
synergistic cell death of AML cells. In addition, xenograft studies demonstrated 
that combination therapy induced a marked reduction in leukemic burden compared 
to control or single agents. Together, the data supports epi-sensitisation as a 
potential component of the strategy for the rational development of combination 
therapies in AML.
INTRODUCTION
Acute myeloid leukaemia (AML) is a heterogeneous 
clonal disorder of immature haematopoietic myeloid cells. 
For over 30 years, the standard induction treatment for AML 
has consisted of a combination of an Anthracycline, such 
as Daunorubicin or Idarubicin, with Cytarabine (Ara-C) 
[1]. With this regimen, a response rate of around 60-80% 
CR can be achieved in younger adults (18 to 60 years old). 
However, in older adults (> 60 years) outcome is poor as 
older patients do not tolerate intensive treatment as well 
as younger counterparts. As AML is considered a disease 
of the aging, with AML occurring most frequently in older 
patients, there is a need for novel less toxic treatments 
such as epigenetic therapies [1–3]. Histone deacetylase 
(HDAC) enzymes are key regulators of chromatin structure 
and post translational modifiers of both histones and non-
histone proteins. HDAC enzymes promote a deacetylated 
state by removing acetyl groups from specific residues and 
function dynamically with histone acetyltransferases (HAT) 
that add acetyl groups back. Regulating transcriptional 
activation through chromatin conformation [4–6] and 
targeting HDACs is an attractive therapeutic option [7–
9]. HDAC inhibitors (HDACi) offer varying selectivity 
towards HDACs, where they can inhibit more than one 
HDAC class (pan-) or single HDACs or classes (selective) 
[5]. Related toxicities for HDACi are low [7, 10], which 
may be particularly beneficial to vulnerable and elderly 
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AML patients. Vorinostat (suberoylanilide hydroxamic 
acid, SAHA) is a hydroxamic acid derivative that inhibits 
the class I and II HDACs (HDAC1, 2, 3 and 6) and is 
only one of four HDAC inhibitors approved for clinical 
use by the FDA (Food and Drug Administration, US) [11, 
12]. Vorinostat has proven efficacy in restoring aberrant 
acetylation in a number of cancers, including both solid and 
haematological malignancies [13]. It is in phase II clinical 
trials (NCT00305773, cliinicaltrials.gov) in AML as a 
monotherapy and has since entered clinical trials as part of 
a combination therapy with several different agents [14].
Non-histone proteins can also be modified by 
HDACs and subsequently HDACi inhibition of HDAC6 
also leads to acetylation of its substrate α-tubulin, 
inducing changes in cell motility [15]. Other forms of 
cell regulation affected by the acetylation of non-histone 
proteins as a result of HDAC inhibition with Vorinostat 
include cell proliferation (i.e. p53), DNA damage repair 
(i.e. Ku-70) and cell cycle (i.e. p21WAF1/CIP1) [6, 16–18]. 
However, the exact mechanism of how Vorinostat 
selectively targets cancer cells and achieves an effective 
clinical response in CTCL and other malignancies is not 
fully understood [10, 13].
A trial of Vorinostat as a monotherapy in 
advanced haematological malignancies identified a 
molecular response, histone H3 hyper-acetylation, in all 
patients. Of the 41 patients enrolled, 7 patients (17%) 
achieved complete response (CR), complete response 
with insufficient haematological recovery (CRi), or 
haematological improvement. Importantly, all 7 patients 
were diagnosed as having AML [19]. Although these 
results are encouraging, a larger proportion of AML 
patients were non-responsive or resistant to Vorinostat.
Better understanding of the mechanisms of action of 
epigenetic therapies are needed to establish their efficacy 
as either mono- or combination therapies [20]. In this 
study, we sought to further characterise the mechanisms of 
the HDACi Vorinostat through integrated ChIP-SEQ and 
gene expression analysis to identify potential novel, but 
rational, therapeutic combinations for Vorinostat.
RESULTS
Vorinostat exhibits potency in AML cell lines
Vorinostat exhibited greater potency at 72 hours 
(IC50 0.42 μM) compared to the 24 hour time point (IC50 
1.55 μM; Figure 1A). A sub-IC50 dose of Vorinostat at 
24 hours (1 μM) was sufficient to result in measurable 
acetylation of lysine 9 of histone H3 (Figure 1B). No 
changes in total histone H3 protein levels were observed. 
Therefore, the Vorinostat-treatment chosen for subsequent 
experiments was 1 μM for 24 hr. The OCI-AML3 cell 
line, which harbours a nucleophosmin (NPM1) mutation, 
exhibited a similar level of toxicity compared to HL-60, 
NB4 and U937 AML cell lines not carrying this mutation 
(Supplementary Figure 1A). Vorinostat induced toxicity 
was identified in HoxA9/Meis1 derived leukemic murine 
bone marrow but not in normal murine bone marrow 
(NBM) (Supplementary Figure 1B), an attractive aspect of 
HDACi especially in a disease of the elderly such as AML.
Profiling Vorinostat induced changes in gene 
expression
OCI-AML3 cells were treated for 24 hours 
with 1 μM Vorinostat and changes in gene expression 
examined using Affymetrix gene expression microarrays 
(Affymetrix™ GeneChip® Human Genome U133 Plus 
2.0 Array). Possible confounding effects of DMSO 
treatment were controlled. Gene expression profiling 
and subsequent normalisation identified significantly 
Figure 1: Vorinostat induced cell death and histone acetylation in AML cell lines. (A) MTT cell proliferation assay derived 
dose response curves, for the OCI-AML3 AML cell line. OCI-AML3 cells were treated with Vorinostat for either 24 or 72 hours. Percentage 
of cell proliferation was calculated relative to DMSO (vehicle) control cells. IC50 values for the time points are shown in the table. (B) 
Western blot analysis confirmed that OCI-AML3 cells treated with 1 μM of Vorinostat for 24 hours, versus control conditions, was sufficient 
to inhibit HDACs as demonstrated by the acetylation of histone H3, and more specifically lysine 9 of H3.
Oncotarget67893www.impactjournals.com/oncotarget
differentially expressed genes, as expected due to it being 
an epigenetic modifying agent. To focus on prominent 
changes and pathways, the stringency for significance 
was set at a fold change of greater or less than 2-fold 
with an unadjusted p-value of <0.05. This identified 142 
genes down-regulated by Vorinostat and 204 genes up-
regulated (Figure 2A) (Supplementary Table 1). The top 
5 up- and down-regulated differentially expressed genes 
(Figure 2B table) were validated by quantitative real-time 
PCR analysis (RQ-PCR). The RQ-PCR confirmed the 
directionality of the array findings which underestimated 
the extent of the fold-change tabulated in (Figure 2B). In 
silico functional analysis was undertaken using DAVID 
(Database for Annotation, Visualisation, and Integrated 
Discovery) (available from http://david.abcc.ncifcrf.gov/) 
which identified that the significantly enriched biological 
functional groups associated with the differential genes 
were chromosome organisation and cell cycle; DNA 
damage response and positive regulation of transcription 
(Figure 2C).
H3K9 is acetylated with Vorinostat treatment
Vorinostat is known to promote acetylation of a 
number of lysine residues along histone H3 and H4; 
however one of the most abundantly modified lysines 
is the activating histone mark lysine 9 on histone H3 
(H3K9) [21]. Due to the distinct and accepted role of 
the acetylation of H3K9 as a marker of transcriptional 
activation [22, 23] it is therefore of interest to further the 
knowledge of Vorinostat within AML gene occupancy at 
the acetylated lysine 9 of histone H3 (Figure 1B). It was of 
interest to determine where H3K9 acetylation was enriched 
with regards to the transcriptional start site (TSS) and 
whether Vorinostat induces any changes to this. Chromatin 
from OCI-AML3 cells treated with 1 μM Vorinostat, or 
DMSO, for 24 hrs was isolated and DNA associated with 
H3K9 acetylation was immuno-precipitated. Template 
positive Ion Sphere Particles were run on the Ion PGM™ 
platform, the resulting data was indexed and aligned to 
hg19 using Bowtie2 [24, 25]. Histone H3K9 acetylation 
enriched peaks were identified using SICER [26] whilst 
ChIP Peak was used to develop composite profiles for 
the region spanning the TSS. These were plotted using 
the tag densities of the H3K9Ac samples and were 
expressed as a fold change relative to the input control 
for both Vorinostat (Figure 3A) and DMSO (Figure 3B) 
treatments. The DMSO sample had increased acetylation 
of H3K9 away from the TSS in up- or downstream by 
more than 1 kb. However, treatment with Vorinostat 
enriched H3K9Ac within 1 kb of the TSS. The intensity 
of this also increased, with the DMSO showing a peak tag 
density (log2 fold change) of approximately 3.75, whereas 
with Vorinostat induced acetylation of approximately 8.5. 
This reinforced that Vorinostat induces H3K9 acetylation, 
particularly with an enrichment close to the TSS (<1 kb).
Vorinostat modulated pathways and networks
All significant ChIP-SEQ peaks (p-value (FDR) 
<0.05) of good quality (Phred score >15), between the 
DMSO control and Vorinostat treated H3K9Ac datasets, 
were mapped to the closest Entrez Gene ID using 
HOMER. This identified genes which were significantly 
enriched for H3K9Ac and those associated with 
significantly less H3K9Ac. Unsurprisingly 93% (13429 
genes) of the Vorinostat induced differentially acetylated 
genes were only associated with H3K9Ac enrichment, 
whereas only 946 (7%) of genes showed a decrease in 
H3K9Ac. Interestingly, 735 (5%) genes demonstrated 
both acetylated and deacetylated H3K9Ac in response to 
Vorinostat treatment (Figure 3C).
Gene Ontology (GO) analysis was performed 
on the genes associated with an increased acetylation 
(13429 genes) and showed that cell death, cell cycle, cell 
proliferation and metabolism were significant (p<0.05). 
This resulted in 760 GO enriched pathways (Figure 
3D). Surprisingly, of these 27% of these, 208 biological 
processes were found to be significant (p<0.05).
Further analysis using the online protein mapping 
tool STRING identified four networks (Supplementary 
Figure 2). Several genes from these networks associated 
with cell proliferation, metabolism, cell death, and cell 
cycle were selected for further analysis (Figure 4A–4D 
respectively), although only 50% of these showed a 
correlation between increased gene acetylation and 
increased expression.
Integrated analysis identifies genes associated 
with induced acetylation and increased expression
Microarray data and enriched genes form the 
ChIP-SEQ study were integrated to provide a more 
comprehensive view of mechanism of action of Vorinostat. 
The 176 genes identified as showing up-regulation from 
the transcriptomic analysis were overlapped with the 
2613 genes associated with a Vorinostat induced increase 
in H3K9Ac binding and Pol II binding (a marker of 
transcriptional activity). This resulted in only an overlap 
of 32 genes (Figure 5A). However, when Pol II was 
removed from data filtering, 136 genes were found to 
have increased gene expression and increased acetylation, 
suggesting that H3K9Ac is not only a marker of pre-
transcriptional signalling, but also of transcribed genes. 
Comparison of genes associated with a decrease in gene 
expression (137) and a decrease in H3K9Ac enrichment 
(946), identified 6 genes in the overlap (Figure 5B). 
Further protein-protein interactions analysis in STRING 
resulted in identification of a network of 48 linked genes 
associated with both increased acetylation and expression 
(Supplementary Figure 3). Ten genes were selected and 
validated by RQ-PCR as being up-regulated following 
Vorinostat treatment (Figure 5C).
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SHH is an epigenetic induced therapeutic target
Our analysis identified a number of antagonistic 
up-regulated genes in response to epigenetic priming of 
the genome by Vorinostat. However, these epigenetic 
induced targets provide an attractive platform for 
combination therapy. SHH has been reported to be 
associated with adverse effects in leukaemia [27]. The 
modest upregulation of SHH mRNA expression following 
Vorinostat treatment (Figure 4C), was verified at the 
protein level in a dose dependent manner in two AML cell 
lines, OCI-AML3 (Figure 6A) and HL-60 (Supplementary 
Figure 4A). As proof of principal, we tested the tested 
the potential of inhibiting SHH as a rational partner for 
combination therapy. SANT-1, a high affinity antagonist 
of smoothened (SMOH), was ineffective at inducing 
cell death as a single agent in the OCI-AML3 and HL-
60 cell line models (Figure 6B). To assess whether the 
efficacy of SANT-1 could be improved by combining 
it with Vorinostat, varying concentrations of SANT-1 
were used with a 1 μM dose of Vorinostat, and drug-dose 
response [28] measured to establish combination indices 
(CIs) (Figure 6C). The combination index demonstrated 
potent synergy across most concentrations used with 
CIs indices <1. Although a concentration of SANT-1 of 
2.5 μM had the highest synergy with 1 μM Vorinostat, a 
lower concentration of 0.1 μM of SANT-1 was also used 
for further studies to establish a minimum effective dose 
with limited potential toxicity for future extension into 
pre-clinical models.
To confirm whether the combination of Vorinostat 
and SANT-1 was efficacious, OCI-AML3 cells were 
treated for 24 hours with sequential treatment of 1 μM 
Vorinostat and low dose (0.1 μM) or high dose (2.5 μM) 
SANT-1, or as single agents. The extent of cell death, 
measured by the CellTiter-Glo® Luminescent Cell 
Viability Assay, significantly increased with both low and 
high dose combination treatment (~25% and ~27.5%) 
compared to Vorinostat only treatment (~12%) which was 
the next most potent treatment (Figure 6D). This trend 
was also observed in the HL-60 cell line, demonstrating 
a significant increase in cell death high dose SANT-1 
with Vorinostat opposed to Vorinostat treatment alone 
(Supplementary Figure 4B). Cell cycle analysis of 
Figure 2: Profiling Vorinostat induced gene expression alterations in OCI-AML3 cells. (A) Unsupervised hierarchical 
clustering of significantly differentially expressed genes in OCI-AML3 cells treated with either DMSO control conditions or 1 μM 
Vorinostat for 24 hours. The blue and red bars to the left of the heatmap show Vorinostat and DMSO samples respectively. On the heatmap, 
blue regions are indicative of low gene expression (142 genes down-regulated by Vorinostat), whereas high expression is represented by red 
regions (204 genes up-regulated by Vorinostat). (B) The top-5 most significantly up- and down-regulated genes were validated by RQ-PCR, 
and normalised to GAPDH. Data represents 3× technical replicates and 3× biological replicates. Significance, as calculated by two-way 
ANOVA, is denoted as * = P<0.05, ** = P<0.01 and *** = P<0.001. (C) The top biological pathways associated with significant alterations 
in gene expression. Of the 346 probe sets corresponding to the genes inputted, 313 were recognised by DAVID.
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combining a concentration of 1 μM of Vorinostat with low 
dose SANT-1 (0.1 μM) showed a significant increase in 
SubG1 (p<0.0005) compared to the DMSO treated profile 
in the OCI-AML3 cell line (Supplementary Figure 4C). 
Limited changes in SubG1 populations were evident 
between combination and Vorinostat as a single agent. 
However, protein analysis identified a modest reduction 
in SHH with OCI-AML3 cells treated with the Vorinostat/
SANT-1 combination than those treated with Vorinostat 
alone (Figure 6E). Interestingly the combination treatment 
induced a marked increase in histone H3 acetylation over 
Vorinostat alone. Gene expression analysis revealed 
a repression of SHH following low dose combination 
treatment, returning expression to basal levels compared 
to Vorinostat alone (Figure 6F). In response to this we 
looked at the downstream regulator of the sonic hedgehog 
pathway, PTCH1, and WNT1, a sonic hedgehog crosstalk 
signalling pathway. In response to the combination 
treatment PTCH1 was induced to significant levels 
compared to the DMSO vehicle control (P<0.001). WNT1 
mRNA expression was significantly increased with 
combination therapy compared to the DMSO control 
(P<0.01), and elevated to a greater extent (P<0.05) than 
the Vorinostat only treatment.
Reduced leukaemia burden in Vorinostat-SANT-1 
treated recipient mice
OCI-AML3 cells which were retro-virally 
infected with a firefly luciferase marker, selected and 
subsequently treated for 24 hours with four treatment 
arms namely: DMSO, 1 μM Vorinostat, 2.5 μM SANT-
Figure 3: Identifying the global changes in the acetylation landscape in response to Vorinostat in AML cell lines with 
ChIP-SEQ. Composite profiling of regions spanning the Transcription Start Sites (TSS) using histone H3 lysine 9 (H3K9) acetylation 
tag densities following treatment with either (A) Vorinostat or (B) DMSO vehicle control. The grey vertical line represents the TSS. (C) 
BioVenn diagram of Vorinostat induced acetylation and deacetylation of H3K9. Significant peaks (p-value (FDR) <0.05) and of good 
quality (Phred score >15) between the DMSO control and Vorinostat treated H3K9Ac datasets, were mapped to the closest Entrez Gene ID 
using HOMER, resulting in two genes lists; those significantly enriched for H3K9Ac and those associated with significantly less H3K9Ac. 
(D) Gene Ontology analysis of the 13429 genes associated with a significant increase in acetylation, following Vorinostat treatment, 
identified 208 biological processes that were significantly enriched.
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1 or 1 μM Vorinostat + 2.5 μM SANT-1 (Figure 7A). 
Two NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice for 
each treatment arm were injected with 1.5x106 cells 
via tail vein. Leukaemia burden was followed via serial 
bioluminescent imaging at days 15, 20 and 28. At day 
20, all mice from all treatment arms have evidence of 
leukaemia burden (Figure 7B). At day 28, no reduction 
in leukaemia burden was observed in mice receiving 
the DMSO vehicle control or SANT-1 treated cells. 
Recipients of the Vorinostat treated cells showed a 
modest reduction in leukaemia growth compared to 
control or SANT-1 treatment arms. However, the most 
striking reduction in leukaemia burden was seen with the 
Vorinostat and SANT-1 combination treatment at day 28. 
Combination therapy also extended life by an average of 
6 days compared to Vorinostat, the next most effective 
treatment.
DISCUSSION
It is well established that both genetics and 
epigenetics play a part in the development of cancer 
[29–31]. Epigenetic gene regulation involves heritable 
changes to the chromatin which do not change the 
DNA sequence, which include DNA methylation and 
chromatin remodelling [32]. The epigenetic landscape 
and regulation of AML has been shown to be aberrant and 
therefore provides attractive therapeutic targets [29, 30, 
33, 34]. However, the characterisation of these epigenetic 
modifiers, including Vorinostat, remains incomplete. 
With resistance to Vorinostat evident from clinical trials, 
and insufficient activity to warrant using Vorinostat as 
a monotherapy, a better understanding of the drug is 
crucial [19, 31, 35]. This cell-line based study aimed to 
understand the mechanisms of Vorinostat on cell death, 
Figure 4: Identifying the biological processes associated with changes in Histone H3K9 acetylation. Gene lists associated 
with specific biological functions of interest, those which feature in the functional annotation of the ChIP-SEQ dataset were compiled and 
subjected to network analysis. The genes which were identified as central to these networks were selected for further validation by RQ-PCR 
in networks associated to (A) cell proliferation, (B) metabolism, (C) cell death and (D) cell cycle. Data is presented as a fold change relative 
to the DMSO control, whereby any genes below the x-axis are down-regulated and those above, up-regulated. Experiment was carried out 
in a biological replicate of three. Significance, as calculated by two-way ANOVA, is denoted as * = P<0.05, ** = P<0.01 and *** = P<0.001.
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ultimately providing a more comprehensive analysis of 
Vorinostat by combining gene expression data with genes 
identified as being associated with acetylated H3K9. From 
this, the functional characterisation of the consequence of 
treating a cell with the HDAC inhibitor Vorinostat has 
been elucidated, including the identification of several, 
epigenetic primed or epigenetically induced therapeutic 
targets for a more rational approach to combination 
therapies [36, 37].
The regulatory processes of HDAC inhibition 
were underlined with transcriptome analysis of the OCI-
AML3 myeloid cell line in the presence and absence of 
Vorinostat. The Vorinostat signature we observed was 
significantly enriched for regulators of the cell cycle, cell 
proliferation and the DNA damage response. Our analysis 
into the global impact Vorinostat has on histone H3K9 
acetylation, identified enrichment around gene promoters 
and downstream of the TSS of active genes following 
treatment [38]. It is suggested that the acetylation of 
promoter regions surrounding the TSS, may provide 
stability for the binding of other chromatin remodelling 
factors and facilitate in RNA Pol II binding [38, 39].
Furthermore, our data reinforced the broad 
biological functions altered in the HDAC equilibrium. 
Of the 760 pathways enriched, 27% were enriched in 
cellular functions including key biological process such as 
proliferation, cell cycle and cell death. The involvement of 
the latter function fits well with our previously published 
work where we reported that Vorinostat can potently 
down-regulate the anti-apoptotic protein C-FLIP in 
AML [40]. As acetylation islands are reported to predict 
functional drivers, the integration of transcriptomics data 
and acetylation sequencing is a logical step in driver 
discovery [38, 41].
By priming, or epi-sensitising, cells with the 
epigenetic modifier Vorinostat, possible induced 
Figure 5: Integrative analysis of Vorinostat induced gene expression changes and alterations in the H3K9 acetylation 
landscape. BioVenn diagrams of to determine overlaps between (A) genes with an increase in expression and an increased H3K9Ac 
binding (left) and genes with an increase in expression and genes associated with an increase in H3K9Ac and Pol II binding (right) 
(B) genes with a decreased expression and a decrease in H3K9Ac binding. Genes in the overlaps, 136 for the increased acetylation/
increased expression and 6 for the decreased acetylation/decreased expression, were mapped for protein-protein interactions in STRING, 
with (C) expression of genes central for the networked measured by RQ-PCR. Experiment was carried out in a biological replicate of three. 
Significance, as calculated by two-way ANOVA, is denoted as * = P<0.05, ** = P<0.01 and *** = P<0.001.
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therapeutic targets could be identified through 
transcriptomic analysis and deep sequencing. Our 
analysis process has identified that, amongst others, the 
sonic hedgehog signalling pathway may be a potential, 
and detrimental, target due its pathway activation. SHH 
is usually inactivated in adult human tissues [42] but 
aberrant activation of the hedgehog pathway has been 
reported in a number of cancers [43–46], with it being 
noted as a driver in medulloblastoma [47]. Furthermore 
in a haematological setting, the activation of components 
of the pathway have aided in CML progression [27] 
and has been cited to promote the self-renewal capacity 
of human leukaemia cells and has a role in malignant 
potential in myeloid leukaemia [48, 49]. The use of the 
SHH inhibitor SANT-1 has shown encouraging results 
as a monotherapy or in combination with other agents 
[50, 51]. Whilst SANT-1 demonstrated little efficacy as 
a single agent in our study it proved to have high synergy 
when combined with Vorinostat both in vitro and in an 
in vivo xenograft model. Strikingly, mice injected with a 
single bolus of combination therapy treated cells exhibited 
a profound reduction in leukaemia burden compared to 
other treatment arms.
The concept of epi-sensitisation, epigenetically 
priming cancers prior to chemotherapy, is becoming more 
accepted, with growing evidence that epigenetic agents are 
altering the transcriptional potential of cancer cells [36, 
52, 53]. In addition, clinical trials are highlighting some 
lower than expected response rates, relapse and evidence 
of drug resistance a persisting problem. In a clinical setting 
epi-sensitisation, in combination with rational therapeutic 
agents, may provide greater response rates.
MATERIALS AND METHODS
Cell lines
The AML cell lines HL-60, U937, NB4 and OCI-
AML3 (DSMZ, Berlin, Germany) were maintained in 
RPMI 1640 media with L-Glutamine, supplemented 
Figure 6: The sonic hedgehog signalling pathway is a therapeutic target for combination therapy. SHH expression was 
measured in (A) OCI-AML3 cells treated with Vorinostat or DMSO for 24 hrs. Equal loading was confirmed with β-Actin. (B) SANT-1 
dose response in AML cell lines after 24 hours. Cell viability was calculated relative to the DMSO control. (C) Combination Index (CI) for 
24 hour treatments of 1 μM Vorinostat with a concentration of 0.1, 1.0 or 2.5 μM of SANT-1. Data represents a biological replicate of 3. 
Values shown indicate that most combinations are synergistic (CI < 1). (D) Percentage cell death of OCI-AML3 cells was measured using 
the CellTiter-Glo® viability assay following 24 hours treatment with either sequential treatment of 1 μM Vorinostat with low (0.1 μM) or 
high dose (2.5 μM) SANT-1, or single agents.  Data represents a biological replicate of 3, with data presented relative to the DMSO control 
(0% cell death). (E) Protein expression of SHH was measured following 24 hours treated with the four treatment strategies in OCI-AML3 
cells. Equal loading was confirmed with β-Actin. (F) SHH gene expression was analysed with RQ-PCR. Experiment was carried out in a 
biological replicate of three. Significance, as calculated by two-way ANOVA, is denoted as * = P<0.05, ** = P<0.01 and *** = P<0.001.
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with 10% Fetal Calf Serum (FCS) and 5% Penicillin/
Streptomycin (Penicillin 100 μg/μl: Streptomycin 100 μg/
μl) (Thermo Fisher Scientific, Paisley, UK).
Trypan blue exclusion assay
In brief, 20 μl of cell suspension was mixed with 
an equal volume of Trypan Blue dye (Invitrogen Life 
Technologies, Paisley, UK) and incubated for 5 min. Cells 
were counted using a haemocytometer.
MTT cell viability assay
MTT solution was prepared following 
manufacturer’s instructions. In brief, 100 μl of cells with 
varying drug concentration, was dispensed in triplicate into 
a 96 well plate for both 24 and 72 hour time points, and 10 
μl of prepared MTT solution (5 mg/ml) (Sigma-Aldrich 
Company Ltd., Germany) added. Plates were incubated for 
3 hours at 37°C, and centrifuged at 200 X g for 5 minute. 
Supernatant was removed and the pellet was resuspended 
in 200 μl of DMSO before reading the plates at 590 nm 
using the Tecan Plate Reader, and Magellan software.
CellTiter-Glo® luminescent cell viability assay 
and combination indices (CI)
The CellTiter-Glo® assay reagents were prepared as 
per the manufacturers recommended instructions. Into a 
white 96-well plate (Nunc™, Thermo Fischer Scientific), 
25 μl of cell suspension was added along with 25 μl of 
prepared CellTiter-Glo® reagent. Plates were incubated 
for 30 minutes at room temperature. Luciferase activity 
was determined using a luminometer. To measure the 
dose–effect relationship of each drug and its combination 
and to determine synergy, CIs were calculated using the 
Calcusyn software package (BioSoft). CI values less than 
1 are considered synergistic.
Figure 7: Vorinostat and SANT-1 combination reduces cancer burden in an AML xenograft model. (A) Outline 
experimental design for AML xenografts derived from OCI-AML3 cells transduced with firefly luciferase, selected, and drug treated for 
24 hours with DMSO vehicle control, 1 μM Vorinostat, 2.5 μM of SANT-1 or combination treatment. Treated cells were transplanted into 
NSG mice (n=2) via tail vein. (B) Mice were imaged at days 15, 20 and 28 to assess cancer burden. Mice were sacrificed at the first sign 
of disease and survival extension was assessed. Average survival post-transplant for each treatment arm were as follows: D29.5 (DMSO), 
D30 (Vorinostat), D31 (SANT-1) and D36 (Vorinostat and SANT-1).
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RNA extraction and microarray
Total RNA was isolated by RNeasy kit (Qiagen, 
Manchester, UK). Eluted RNA was quantified using 
the Nanodrop ND-1000 Spectrophotometer (Thermo 
Scientific, Delaware, USA). Screening of total RNA 
samples against the Affymetrix™ GeneChip® Human 
Genome U133 Plus 2.0 Array followed the Microarray 
Sample Preparation Protocol as developed by Roche 
(Roche Diagnostics Ltd, West Sussex, UK) as part of 
the MILE study (23). The generated CEL files were 
saved and imported into Partek Genomics Suite 6.0 for 
bioinformatics analysis. Microarray data are available 
at the Gene Expression Omnibus (GEO) repository, 
accession number GSE86445. Matched samples were used 
for both the microarray and ChIP-SEQ.
Quantitative real-time PCR
cDNA was prepared from 1 μg aliquots of RNA 
using a High Capacity cDNA Reverse Transcription Kit 
(Qiagen, Crawley, UK) and diluted 1 in 20 in DEPC-
treated water to give a working stock. For quantitative 
real-time PCR, 12.5 ng aliquots of cDNA were amplified 
in triplicate on an ABI 7500 real-time PCR system using 
SYBR® Green primers FastStart SYBR Green Master Mix 
(Rox) (Roche Diagnostics Ltd, West Sussex, U.K), and 
primers for human genes or endogenous control GAPDH. 
The endogenous control GAPDH, had previously 
been verified as being suitable reference genes for the 
cell line used using the geNorm assay (Primerdesign, 
Southampton, UK). Relative quantification was carried out 
and calibrated to control samples where appropriate. Data 
was analysed using the standard software for the ABI 7500 
real-time PCR system. All primers used for SYBR® Green 
RQ-PCR were designed in Primer-BLAST, a specific 
primer finding tool (http://www.ncbi.nlm.nih.gov/tools/
primer-blast) using sequences imported from NCBI Gene. 
Primers were ordered from Integrated DNA Technologies 
(IDT) and diluted using the relevant volume of nuclease-
free water. Primers were assessed by melt curve analysis 
following RQ-PCR. Primer sequences are listed in the 
Supplementary Materials (Supplementary Table 2).
Protein extraction and quantification
Cells were pelleted by centrifugation at 200 X g for 
5 minutes and resuspended in 200 μl RIPA buffer with a 
protease inhibitor cocktail (Sigma-Aldrich Company Ltd., 
Germany). Lysates were incubated on ice for 30 minutes 
before centrifuging at 10,000 X g for 20 minutes to remove 
cell debris. Protein concentrations were determined using 
the BCA Protein Assay Reagent (Pierce, Rockford, IL). 
Thirty to 50 μg of protein lysates were resolved by SDS-
polyacrylamide gel (12%). The gels were electroblotted 
onto nitrocellulose membranes (Hybond-P, Amersham, 
GE Healthcare). Antibody staining was performed with 
a chemiluminescence detection system (Supersignal; 
Pierce). PARP (14-6666;eBioscience, Cheshire, UK), 
SHH (ab53281; Abcam, Cambridge, UK), hyperacetylated 
histone H3 (#9715; Cell Signalling,Leiden, NL), 
H3K9Ac (#9649; Cell Signalling, Leiden, NL) and 
acetylated α-tubulin (#3971; Cell Signalling, Leiden, 
NL) monoclonal antibodies were used in conjunction 
with a horseradish peroxidase (HRP)-conjugated sheep 
anti-mouse or anti-rabbit secondary antibody (P0447 and 
P0448; Dako, Denmark). Equal loading was assessed 
using a β-actin mouse monoclonal primary antibody 
(Sigma, Poole, Dorset, UK).
Flow cytometry
Cells were fixed by the addition of 1 ml of ice cold 
70% ethanol to cell pellets, and resuspended by pipetting 
up and down. Cells were pelleted by centrifugation at 
200 X g for 5 minutes, and resuspended in PI (propidium 
iodide (40 μg/L)/ RNase solution (20 μg/L)) in PBS. 
Samples were incubated at 37°C for 30 minutes before 
analysing using the BD LSR II and the BD FACSDiva 
Software (BD Biosciences, Oxford, UK).
Inhibitors
The HDAC inhibitor Vorinostat and sonic hedgehog 
pathway inhibitor SANT-1 (Selleck Chemicals, Munich, 
Germany), were prepared in high purity DMSO, and 
stored in aliquots at -80°C until required.
Chromatin immunoprecipitation and deep 
sequencing (ChIP-SEQ)
Following 24 hour treatment with either 1 μM 
Vorinostat or control conditions, 2x106 OCI-AML3 cells 
were washed and pelleted. ChIP was achieved using the 
MAGnify™ Chromatin Immunoprecipitation System 
(Thermo Fisher Scientific, Paisley, UK) following the 
manufacturer’s guidelines, with additional optimisation 
where needed. In brief, chromatin was crosslinked in a 
final concentration of 1 % formaldehyde for 10 minutes 
recommended by the protocol, and resuspended to 
2 million cells per 500 μl of lysis buffer into 1.5 ml TPX 
microtubes (Diagenode, Liège, Belgium). The Bioruptor® 
UCD-200 was used to generate 100-300 bp fragments. To 
optimise the shearing, 1.5 ml TPX microtubes of prepared 
chromatin high was sonicated for 15 seconds ON/OFF for 
three 5 minute intervals, followed by a 7-minute interval 
(5 min, 5 min, 5 min, 7 min). Ice was replenished between 
each interval. Before proceeding with the protocol, 
the sonication of fragments to the appropriate size was 
evaluated on a 2% DNA gel. Sonicated chromatin was 
diluted to 2x106 cells/ml. The IP was performed by binding 
10 μg of antibody, H3K9Ac (49-1009), Pol II (9-1033) or 
IgG controls (Thermo Fisher Scientific, Paisley, UK) to 
Dynabeads® (Thermo Fisher Scientific, Paisley, UK), 
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and incubating overnight at 4°C with 100 μl (2x105cells). 
Samples and controls were reverse crosslinked with 
Proteinase K and purified with DNA Purification Magnetic 
Beads before eluting in 50 μl of elution buffer. Ion ChIP-
SEQ libraries were prepared and adapters added using 
the Ion Xpress Fragment Kit (Thermo Fisher Scientific, 
Paisley, UK). After the library preparation, the quality of 
the library was assessed by the Agilent 2100 Bioanalyzer™ 
instrument with Agilent High Sensitivity DNA Kit (Agilent 
Technologies, Cheshire, UK). Libraries were diluted with 
Low TE buffer to a final concentration of 15 pM. Ion 
Sphere Particles were prepared with the template positive 
libraries using the Ion OneTouch™ System. After setup 
and initialisation of the Ion OneTouch™ System, an 
amplification solution was prepared and installed, and 
ISPs enriched as per the Ion OneTouch™ 200 Template 
Kit v2. Following the removal and washing of the enriched 
ISPs, the ISPs were stored at -20°C until sequencing. 
The sequencing of the prepared ISPs, using the PGM™ 
platform, was performed as per the Ion Sequencing Kit 
User Guide v2.0, along with the relevant reagents in the 
Ion PGM™ Supplies Kit, Ion Sequencing Reagents Kit 
and Ion PGM™ Reagents Kit on the Ion 318™ Chips 
(Thermo Fisher Scientific, Paisley, UK).
The FASTQ files from the Torrent Server were 
sorted and aligned using Bowtie2 [24, 25] resulting 
in a SAM file (Sequence Alignment Map) which was 
converted to a BAM file (Binary Alignment Map) whilst 
the quality of reads was assessed using the MAPQ 
(MAPping Quality). Using BEDtools, files were converted 
from BAM files to BED files [54] for viewing in the 
Integrated Genomics Viewer (IGV) (available from http://
www.broadinstitute.org/igv/) [55, 56].
Enriched ChIP regions were identified using the 
peak finder SICER (window size of 400 bp and a gap 
size of 1200 bp) [26]. The peaks identified were then 
mapped to the nearest gene via Entrez ID using HOMER, 
(Hypergeometric Optimization of Motif EnRichment) 
[57]. The HOMER files were imported into Partek 
Genomics Suite 6.0 whereby Gene Ontology analysis 
could be carried out to determine the functionality of the 
genes enriched.
Xenografts
OCI-AML3 cells were seeded the day before 
transfection at 5x106 cells/10 cm dish and grown to 
approximately 70-80% confluency. Transfection of 293T 
cells was performed using Turbofect (Thermo Scientific, 
Massachusetts, USA) with a molar of 1:3:6 ratio of VSV-G 
envelope vector pMD2.G, packaging vector psPAX2, and 
firefly luciferase vector pSLIEW (kindly provided by 
Prof Olaf Heidenreich). Viral supernatant was harvested 
and filtered 72 hours after transfection. A volume of 
500μl filtered pSLIEW virus was added to 2x105 cells in 
200 μl medium with 8 μg/ml Polybrene (Sigma Aldrich) 
and incubated for 48 hours before selection in neomycin. 
Validation of OCI-AML3 transduction was performed 
using Bruker In Vivo Xtreme imaging system before cells 
were treated and transplanted.
Cells were treated in vitro with control, each single 
agent and 1 μM Vorinostat plus 2.5 μM SANT-1. As 
2.5 μM SANT-1 showed the greatest synergy in vitro, this 
was brought forward for our xenograft study. A total of 
1.5x106 cells per mouse were counted via Trypan Blue 
staining, resuspended in PBS and transplanted via tail vein 
injection into recipient NSG mice (each treatment group 
n=2). Mice were imaged using the Bruker In Vivo Xtreme 
imaging system three times. Mice were sacrificed at the 
first sign of disease and survival extension was assessed. 
Animal handling followed the guidelines of the UK 
Animals (Scientific Procedures) Act 1986 and were carried 
out under the Home Office License (approval granted 11th 
March 2014, license number PPL2760). Experimental 
procedures were approved by the Animal Welfare Ethical 
Review Board (AWERB), Queen’s University Belfast.
Statistical analysis
Unless otherwise indicated, all data is presented as 
the mean± s.e.m. and P values were calculated by two-
tailed Student’s t-test using GraphPad Prism software. 
Significant statistical differences (*P<0.05, **P<0.01, 
***P<0.001) are indicated.
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